Key Insights
The global Gastroesophageal Reflux Disease (GERD) market, valued at $5.1 billion in 2024, is projected for significant expansion, with a projected Compound Annual Growth Rate (CAGR) of 2.5% from 2024 to 2033. This growth is driven by increasing GERD prevalence due to lifestyle factors and an aging global population. Enhanced diagnostic capabilities and advancements in treatment options, including novel proton pump inhibitors (PPIs) and H2 receptor blockers, further fuel market demand. Key market restraints include potential long-term side effects of certain medications and growing drug resistance. The market is segmented by diagnosis methods, such as upper endoscopy and ambulatory pH monitoring, and by drug classes, predominantly PPIs. Geographically, North America and Europe lead in market share, supported by robust healthcare spending. However, the Asia-Pacific region, driven by rising healthcare awareness and accessibility in economies like China and India, is expected to exhibit substantial growth.
GERD Industry Market Size (In Billion)
The competitive environment features major pharmaceutical corporations and specialized firms vying through product innovation, brand equity, and strategic distribution. Future market expansion will hinge on the development of innovative therapies, refined diagnostic tools, and amplified patient education on preventative lifestyle changes. Strategic collaborations, mergers, and acquisitions are anticipated to reshape the competitive arena, while personalized medicine approaches addressing individual patient needs will become increasingly vital.
GERD Industry Company Market Share
Comprehensive GERD Industry Report: 2019-2033
This in-depth report provides a comprehensive analysis of the GERD (Gastroesophageal Reflux Disease) industry, offering invaluable insights for stakeholders across the value chain. With a focus on market dynamics, competitive landscapes, and future growth trajectories, this report covers the period from 2019 to 2033, with a base year of 2025 and a forecast period of 2025-2033. The report segments the market by diagnosis (Upper Endoscopy, Ambulatory Acid (pH) Probe Test, Esophageal Manometry, Others) and drug type (Proton Pump Inhibitors (PPIs), H2 Receptor Blockers, Others), providing granular market sizing and growth projections valued in Millions.
GERD Industry Market Structure & Competitive Dynamics
The GERD industry exhibits a moderately concentrated market structure, with several multinational pharmaceutical companies holding significant market share. Key players such as Reckitt Benckiser Group PLC, Medtronic, AstraZeneca, Haleon Group of Companies, and Pfizer Inc. dominate the landscape, though numerous smaller players contribute significantly to the overall market. The industry's competitive dynamics are characterized by intense rivalry driven by pricing pressures, product differentiation, and the introduction of innovative therapeutics.
- Market Concentration: The top five players hold an estimated xx% of the global market share (2024), indicating a moderately concentrated market.
- Innovation Ecosystems: Significant investment in R&D leads to the development of novel treatment approaches and diagnostic tools.
- Regulatory Frameworks: Stringent regulatory approval processes influence market entry and product lifecycles.
- Product Substitutes: The availability of over-the-counter (OTC) medications and alternative therapies introduces competitive pressure.
- End-User Trends: Growing awareness of GERD and increasing prevalence contribute to market growth.
- M&A Activities: The industry witnesses significant merger and acquisition (M&A) activity, exemplified by Glenmark Pharmaceuticals' acquisition of OTC drugs from Wockhardt in 2022, demonstrating strategic consolidation and expansion efforts. The total value of M&A deals in the GERD industry between 2019 and 2024 is estimated to be $xx Million.
GERD Industry Industry Trends & Insights
The GERD industry is experiencing robust growth, driven by several key factors. The rising prevalence of GERD globally, coupled with increased healthcare expenditure and improved diagnostics, is a major growth driver. The market is witnessing a shift towards more sophisticated diagnostic techniques, alongside advancements in drug therapies. Technological disruptions, such as the development of novel drug delivery systems and personalized medicine approaches, are further shaping the market landscape. Consumer preference for convenient and effective treatment options fuels the demand for OTC medications and innovative therapies. The CAGR (Compound Annual Growth Rate) of the GERD market is projected to be xx% during the forecast period (2025-2033), with a market penetration rate expected to reach xx% by 2033. Competitive dynamics, including the entry of new players and the ongoing development of biosimilars, contribute to the overall market evolution.
Dominant Markets & Segments in GERD Industry
The North American market currently holds the largest share of the global GERD market, driven by high healthcare expenditure, high prevalence of GERD, and advanced healthcare infrastructure. Within the market segmentation, Proton Pump Inhibitors (PPIs) represent the most dominant drug type due to their efficacy and widespread use. The Upper Endoscopy segment holds a leading position within the diagnostic space due to its diagnostic accuracy.
- Key Drivers of North American Market Dominance:
- High healthcare expenditure.
- High prevalence of GERD.
- Advanced healthcare infrastructure.
- Strong regulatory support for new drug approvals.
- Key Drivers of PPI Dominance:
- High efficacy in acid reduction.
- Wide availability and accessibility.
- Established market presence.
- Key Drivers of Upper Endoscopy Dominance:
- High diagnostic accuracy.
- Wide availability and accessibility.
- Ability to detect other esophageal issues.
The market size for PPIs in 2025 is estimated at $xx Million, while the Upper Endoscopy diagnostic segment is projected to be worth $xx Million.
GERD Industry Product Innovations
Recent product innovations in the GERD industry focus on improving drug efficacy, reducing side effects, and developing more convenient delivery systems. There's a growing emphasis on personalized medicine, tailoring treatment to individual patient needs. Technological advancements are leading to the development of novel diagnostic tools that are less invasive and more precise. These innovations are improving patient outcomes and driving market growth.
Report Segmentation & Scope
This report provides a detailed segmentation of the GERD market by diagnosis and drug type.
By Diagnosis:
- Upper Endoscopy: This segment is expected to experience steady growth due to its diagnostic capabilities. Market size in 2025: $xx Million. Competitive dynamics are influenced by technological advancements and procedural costs.
- Ambulatory Acid (pH) Probe Test: This segment's growth is driven by improved patient convenience. Market size in 2025: $xx Million. Competition hinges on accuracy and cost-effectiveness.
- Esophageal Manometry: This niche segment offers advanced diagnostic information. Market size in 2025: $xx Million. Growth is limited by specialized expertise requirements.
- Others: This segment includes less prevalent diagnostic methods. Market size in 2025: $xx Million. Growth is expected to be moderate.
By Drug Type:
- Proton Pump Inhibitors (PPIs): This segment dominates the market due to high efficacy and widespread use. Market size in 2025: $xx Million. Competition centers on pricing and generic availability.
- H2 Receptor Blockers: This segment offers an alternative treatment option. Market size in 2025: $xx Million. Growth is constrained by the dominance of PPIs.
- Others: This segment comprises other medications for GERD management. Market size in 2025: $xx Million. Growth depends on the success of novel therapies.
Key Drivers of GERD Industry Growth
Several factors drive the growth of the GERD industry. The rising prevalence of GERD due to changing lifestyles is a major driver. Advancements in diagnostic technologies and therapeutic options contribute significantly to market expansion. Furthermore, increasing healthcare expenditure and improved access to healthcare facilities in developing economies fuel market growth. The regulatory landscape, particularly in the approval of new drugs and therapies, also plays a crucial role.
Challenges in the GERD Industry Sector
The GERD industry faces certain challenges including the high cost of advanced diagnostic procedures and medications, which limit access for many patients. The development of generic versions of leading drugs exerts pricing pressure on manufacturers. Furthermore, stringent regulatory requirements can increase the time and costs associated with bringing new drugs to market. Supply chain disruptions and the development of drug resistance are also potential obstacles to market growth. The overall impact of these challenges is estimated to affect the market size by approximately xx% by 2033.
Leading Players in the GERD Industry Market
- Reckitt Benckiser Group PLC
- Medtronic
- AstraZeneca
- Haleon Group of Companies
- TWi Pharmaceuticals Inc
- Glenmark
- Aurobindo Pharma
- Johnson & Johnson
- Teva Pharmaceuticals Industries Limited
- SRS Life Sciences
- Zydus Group
- Takeda Pharmaceutical Co Ltd
- Pfizer Inc
Key Developments in GERD Industry Sector
- June 2022: Glenmark Pharmaceuticals Ltd acquired approved generic versions of famotidine and lansoprazole from Wockhardt Ltd, expanding its presence in the OTC GERD treatment market.
- June 2022: Zydus Lifesciences received FDA approval for its famotidine tablets, increasing competition within the H2 receptor blocker segment.
Strategic GERD Industry Market Outlook
The GERD industry is poised for continued growth, driven by ongoing research and development of new therapies, expanding diagnosis capabilities, and rising disease prevalence. Strategic opportunities exist in developing personalized medicine approaches, innovative drug delivery systems, and affordable treatment options. The focus on improving patient outcomes, coupled with technological advancements, promises significant growth potential for the industry in the coming years.
GERD Industry Segmentation
-
1. Diagnosis
- 1.1. Upper Endoscopy
- 1.2. Ambulatory Acid (pH) Probe Test
- 1.3. Esophageal Manometry
- 1.4. Others
-
2. Drug Type
- 2.1. Proton Pump Inhibitors (PPIs)
- 2.2. H2 Receptor Blockers
- 2.3. Others
GERD Industry Segmentation By Geography
-
1. North America
- 1.1. United States
- 1.2. Canada
- 1.3. Mexico
-
2. Europe
- 2.1. Germany
- 2.2. United Kingdom
- 2.3. France
- 2.4. Italy
- 2.5. Spain
- 2.6. Rest of Europe
-
3. Asia Pacific
- 3.1. China
- 3.2. Japan
- 3.3. India
- 3.4. Australia
- 3.5. South Korea
- 3.6. Rest of Asia Pacific
-
4. Middle East and Africa
- 4.1. GCC
- 4.2. South Africa
- 4.3. Rest of Middle East and Africa
-
5. South America
- 5.1. Brazil
- 5.2. Argentina
- 5.3. Rest of South America
GERD Industry Regional Market Share
Geographic Coverage of GERD Industry
GERD Industry REPORT HIGHLIGHTS
| Aspects | Details |
|---|---|
| Study Period | 2020-2034 |
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026-2034 |
| Historical Period | 2020-2025 |
| Growth Rate | CAGR of 2.5% from 2020-2034 |
| Segmentation |
|
Table of Contents
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 2.1. Introduction
- 3. Market Dynamics
- 3.1. Introduction
- 3.2. Market Drivers
- 3.2.1. Rising Prevalence of Gastrointestinal Reflux Diseases and Changing Lifestyle; Increasing Awareness about GERD
- 3.3. Market Restrains
- 3.3.1. Patent Expiry of Blockbuster Drugs and Frequent Product Recalls
- 3.4. Market Trends
- 3.4.1. H2 Receptor Blockers Segment is Expected to Witness Growth Over the Forecast Period
- 4. Market Factor Analysis
- 4.1. Porters Five Forces
- 4.2. Supply/Value Chain
- 4.3. PESTEL analysis
- 4.4. Market Entropy
- 4.5. Patent/Trademark Analysis
- 5. Global GERD Industry Analysis, Insights and Forecast, 2020-2032
- 5.1. Market Analysis, Insights and Forecast - by Diagnosis
- 5.1.1. Upper Endoscopy
- 5.1.2. Ambulatory Acid (pH) Probe Test
- 5.1.3. Esophageal Manometry
- 5.1.4. Others
- 5.2. Market Analysis, Insights and Forecast - by Drug Type
- 5.2.1. Proton Pump Inhibitors (PPIs)
- 5.2.2. H2 Receptor Blockers
- 5.2.3. Others
- 5.3. Market Analysis, Insights and Forecast - by Region
- 5.3.1. North America
- 5.3.2. Europe
- 5.3.3. Asia Pacific
- 5.3.4. Middle East and Africa
- 5.3.5. South America
- 5.1. Market Analysis, Insights and Forecast - by Diagnosis
- 6. North America GERD Industry Analysis, Insights and Forecast, 2020-2032
- 6.1. Market Analysis, Insights and Forecast - by Diagnosis
- 6.1.1. Upper Endoscopy
- 6.1.2. Ambulatory Acid (pH) Probe Test
- 6.1.3. Esophageal Manometry
- 6.1.4. Others
- 6.2. Market Analysis, Insights and Forecast - by Drug Type
- 6.2.1. Proton Pump Inhibitors (PPIs)
- 6.2.2. H2 Receptor Blockers
- 6.2.3. Others
- 6.1. Market Analysis, Insights and Forecast - by Diagnosis
- 7. Europe GERD Industry Analysis, Insights and Forecast, 2020-2032
- 7.1. Market Analysis, Insights and Forecast - by Diagnosis
- 7.1.1. Upper Endoscopy
- 7.1.2. Ambulatory Acid (pH) Probe Test
- 7.1.3. Esophageal Manometry
- 7.1.4. Others
- 7.2. Market Analysis, Insights and Forecast - by Drug Type
- 7.2.1. Proton Pump Inhibitors (PPIs)
- 7.2.2. H2 Receptor Blockers
- 7.2.3. Others
- 7.1. Market Analysis, Insights and Forecast - by Diagnosis
- 8. Asia Pacific GERD Industry Analysis, Insights and Forecast, 2020-2032
- 8.1. Market Analysis, Insights and Forecast - by Diagnosis
- 8.1.1. Upper Endoscopy
- 8.1.2. Ambulatory Acid (pH) Probe Test
- 8.1.3. Esophageal Manometry
- 8.1.4. Others
- 8.2. Market Analysis, Insights and Forecast - by Drug Type
- 8.2.1. Proton Pump Inhibitors (PPIs)
- 8.2.2. H2 Receptor Blockers
- 8.2.3. Others
- 8.1. Market Analysis, Insights and Forecast - by Diagnosis
- 9. Middle East and Africa GERD Industry Analysis, Insights and Forecast, 2020-2032
- 9.1. Market Analysis, Insights and Forecast - by Diagnosis
- 9.1.1. Upper Endoscopy
- 9.1.2. Ambulatory Acid (pH) Probe Test
- 9.1.3. Esophageal Manometry
- 9.1.4. Others
- 9.2. Market Analysis, Insights and Forecast - by Drug Type
- 9.2.1. Proton Pump Inhibitors (PPIs)
- 9.2.2. H2 Receptor Blockers
- 9.2.3. Others
- 9.1. Market Analysis, Insights and Forecast - by Diagnosis
- 10. South America GERD Industry Analysis, Insights and Forecast, 2020-2032
- 10.1. Market Analysis, Insights and Forecast - by Diagnosis
- 10.1.1. Upper Endoscopy
- 10.1.2. Ambulatory Acid (pH) Probe Test
- 10.1.3. Esophageal Manometry
- 10.1.4. Others
- 10.2. Market Analysis, Insights and Forecast - by Drug Type
- 10.2.1. Proton Pump Inhibitors (PPIs)
- 10.2.2. H2 Receptor Blockers
- 10.2.3. Others
- 10.1. Market Analysis, Insights and Forecast - by Diagnosis
- 11. Competitive Analysis
- 11.1. Global Market Share Analysis 2025
- 11.2. Company Profiles
- 11.2.1 Reckitt Benckiser Group PLC
- 11.2.1.1. Overview
- 11.2.1.2. Products
- 11.2.1.3. SWOT Analysis
- 11.2.1.4. Recent Developments
- 11.2.1.5. Financials (Based on Availability)
- 11.2.2 Medtronic
- 11.2.2.1. Overview
- 11.2.2.2. Products
- 11.2.2.3. SWOT Analysis
- 11.2.2.4. Recent Developments
- 11.2.2.5. Financials (Based on Availability)
- 11.2.3 AstraZeneca
- 11.2.3.1. Overview
- 11.2.3.2. Products
- 11.2.3.3. SWOT Analysis
- 11.2.3.4. Recent Developments
- 11.2.3.5. Financials (Based on Availability)
- 11.2.4 Haleon Group of Companies
- 11.2.4.1. Overview
- 11.2.4.2. Products
- 11.2.4.3. SWOT Analysis
- 11.2.4.4. Recent Developments
- 11.2.4.5. Financials (Based on Availability)
- 11.2.5 TWi Pharmaceuticals Inc
- 11.2.5.1. Overview
- 11.2.5.2. Products
- 11.2.5.3. SWOT Analysis
- 11.2.5.4. Recent Developments
- 11.2.5.5. Financials (Based on Availability)
- 11.2.6 Glenmark
- 11.2.6.1. Overview
- 11.2.6.2. Products
- 11.2.6.3. SWOT Analysis
- 11.2.6.4. Recent Developments
- 11.2.6.5. Financials (Based on Availability)
- 11.2.7 Aurobindo Pharma*List Not Exhaustive
- 11.2.7.1. Overview
- 11.2.7.2. Products
- 11.2.7.3. SWOT Analysis
- 11.2.7.4. Recent Developments
- 11.2.7.5. Financials (Based on Availability)
- 11.2.8 Johnson & Johnson
- 11.2.8.1. Overview
- 11.2.8.2. Products
- 11.2.8.3. SWOT Analysis
- 11.2.8.4. Recent Developments
- 11.2.8.5. Financials (Based on Availability)
- 11.2.9 Teva Pharmaceuticals Industries Limited
- 11.2.9.1. Overview
- 11.2.9.2. Products
- 11.2.9.3. SWOT Analysis
- 11.2.9.4. Recent Developments
- 11.2.9.5. Financials (Based on Availability)
- 11.2.10 SRS Life Sciences
- 11.2.10.1. Overview
- 11.2.10.2. Products
- 11.2.10.3. SWOT Analysis
- 11.2.10.4. Recent Developments
- 11.2.10.5. Financials (Based on Availability)
- 11.2.11 Zydus Group
- 11.2.11.1. Overview
- 11.2.11.2. Products
- 11.2.11.3. SWOT Analysis
- 11.2.11.4. Recent Developments
- 11.2.11.5. Financials (Based on Availability)
- 11.2.12 Takeda Pharmaceutical Co Ltd
- 11.2.12.1. Overview
- 11.2.12.2. Products
- 11.2.12.3. SWOT Analysis
- 11.2.12.4. Recent Developments
- 11.2.12.5. Financials (Based on Availability)
- 11.2.13 Pfizer Inc
- 11.2.13.1. Overview
- 11.2.13.2. Products
- 11.2.13.3. SWOT Analysis
- 11.2.13.4. Recent Developments
- 11.2.13.5. Financials (Based on Availability)
- 11.2.1 Reckitt Benckiser Group PLC
List of Figures
- Figure 1: Global GERD Industry Revenue Breakdown (billion, %) by Region 2025 & 2033
- Figure 2: North America GERD Industry Revenue (billion), by Diagnosis 2025 & 2033
- Figure 3: North America GERD Industry Revenue Share (%), by Diagnosis 2025 & 2033
- Figure 4: North America GERD Industry Revenue (billion), by Drug Type 2025 & 2033
- Figure 5: North America GERD Industry Revenue Share (%), by Drug Type 2025 & 2033
- Figure 6: North America GERD Industry Revenue (billion), by Country 2025 & 2033
- Figure 7: North America GERD Industry Revenue Share (%), by Country 2025 & 2033
- Figure 8: Europe GERD Industry Revenue (billion), by Diagnosis 2025 & 2033
- Figure 9: Europe GERD Industry Revenue Share (%), by Diagnosis 2025 & 2033
- Figure 10: Europe GERD Industry Revenue (billion), by Drug Type 2025 & 2033
- Figure 11: Europe GERD Industry Revenue Share (%), by Drug Type 2025 & 2033
- Figure 12: Europe GERD Industry Revenue (billion), by Country 2025 & 2033
- Figure 13: Europe GERD Industry Revenue Share (%), by Country 2025 & 2033
- Figure 14: Asia Pacific GERD Industry Revenue (billion), by Diagnosis 2025 & 2033
- Figure 15: Asia Pacific GERD Industry Revenue Share (%), by Diagnosis 2025 & 2033
- Figure 16: Asia Pacific GERD Industry Revenue (billion), by Drug Type 2025 & 2033
- Figure 17: Asia Pacific GERD Industry Revenue Share (%), by Drug Type 2025 & 2033
- Figure 18: Asia Pacific GERD Industry Revenue (billion), by Country 2025 & 2033
- Figure 19: Asia Pacific GERD Industry Revenue Share (%), by Country 2025 & 2033
- Figure 20: Middle East and Africa GERD Industry Revenue (billion), by Diagnosis 2025 & 2033
- Figure 21: Middle East and Africa GERD Industry Revenue Share (%), by Diagnosis 2025 & 2033
- Figure 22: Middle East and Africa GERD Industry Revenue (billion), by Drug Type 2025 & 2033
- Figure 23: Middle East and Africa GERD Industry Revenue Share (%), by Drug Type 2025 & 2033
- Figure 24: Middle East and Africa GERD Industry Revenue (billion), by Country 2025 & 2033
- Figure 25: Middle East and Africa GERD Industry Revenue Share (%), by Country 2025 & 2033
- Figure 26: South America GERD Industry Revenue (billion), by Diagnosis 2025 & 2033
- Figure 27: South America GERD Industry Revenue Share (%), by Diagnosis 2025 & 2033
- Figure 28: South America GERD Industry Revenue (billion), by Drug Type 2025 & 2033
- Figure 29: South America GERD Industry Revenue Share (%), by Drug Type 2025 & 2033
- Figure 30: South America GERD Industry Revenue (billion), by Country 2025 & 2033
- Figure 31: South America GERD Industry Revenue Share (%), by Country 2025 & 2033
List of Tables
- Table 1: Global GERD Industry Revenue billion Forecast, by Diagnosis 2020 & 2033
- Table 2: Global GERD Industry Revenue billion Forecast, by Drug Type 2020 & 2033
- Table 3: Global GERD Industry Revenue billion Forecast, by Region 2020 & 2033
- Table 4: Global GERD Industry Revenue billion Forecast, by Diagnosis 2020 & 2033
- Table 5: Global GERD Industry Revenue billion Forecast, by Drug Type 2020 & 2033
- Table 6: Global GERD Industry Revenue billion Forecast, by Country 2020 & 2033
- Table 7: United States GERD Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 8: Canada GERD Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 9: Mexico GERD Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 10: Global GERD Industry Revenue billion Forecast, by Diagnosis 2020 & 2033
- Table 11: Global GERD Industry Revenue billion Forecast, by Drug Type 2020 & 2033
- Table 12: Global GERD Industry Revenue billion Forecast, by Country 2020 & 2033
- Table 13: Germany GERD Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 14: United Kingdom GERD Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 15: France GERD Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 16: Italy GERD Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 17: Spain GERD Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 18: Rest of Europe GERD Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 19: Global GERD Industry Revenue billion Forecast, by Diagnosis 2020 & 2033
- Table 20: Global GERD Industry Revenue billion Forecast, by Drug Type 2020 & 2033
- Table 21: Global GERD Industry Revenue billion Forecast, by Country 2020 & 2033
- Table 22: China GERD Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 23: Japan GERD Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 24: India GERD Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 25: Australia GERD Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 26: South Korea GERD Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 27: Rest of Asia Pacific GERD Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 28: Global GERD Industry Revenue billion Forecast, by Diagnosis 2020 & 2033
- Table 29: Global GERD Industry Revenue billion Forecast, by Drug Type 2020 & 2033
- Table 30: Global GERD Industry Revenue billion Forecast, by Country 2020 & 2033
- Table 31: GCC GERD Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 32: South Africa GERD Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 33: Rest of Middle East and Africa GERD Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 34: Global GERD Industry Revenue billion Forecast, by Diagnosis 2020 & 2033
- Table 35: Global GERD Industry Revenue billion Forecast, by Drug Type 2020 & 2033
- Table 36: Global GERD Industry Revenue billion Forecast, by Country 2020 & 2033
- Table 37: Brazil GERD Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 38: Argentina GERD Industry Revenue (billion) Forecast, by Application 2020 & 2033
- Table 39: Rest of South America GERD Industry Revenue (billion) Forecast, by Application 2020 & 2033
Frequently Asked Questions
1. What is the projected Compound Annual Growth Rate (CAGR) of the GERD Industry?
The projected CAGR is approximately 2.5%.
2. Which companies are prominent players in the GERD Industry?
Key companies in the market include Reckitt Benckiser Group PLC, Medtronic, AstraZeneca, Haleon Group of Companies, TWi Pharmaceuticals Inc, Glenmark, Aurobindo Pharma*List Not Exhaustive, Johnson & Johnson, Teva Pharmaceuticals Industries Limited, SRS Life Sciences, Zydus Group, Takeda Pharmaceutical Co Ltd, Pfizer Inc.
3. What are the main segments of the GERD Industry?
The market segments include Diagnosis, Drug Type.
4. Can you provide details about the market size?
The market size is estimated to be USD 5.1 billion as of 2022.
5. What are some drivers contributing to market growth?
Rising Prevalence of Gastrointestinal Reflux Diseases and Changing Lifestyle; Increasing Awareness about GERD.
6. What are the notable trends driving market growth?
H2 Receptor Blockers Segment is Expected to Witness Growth Over the Forecast Period.
7. Are there any restraints impacting market growth?
Patent Expiry of Blockbuster Drugs and Frequent Product Recalls.
8. Can you provide examples of recent developments in the market?
In June 2022, Glenmark Pharmaceuticals Ltd acquired the approved generic versions of certain over-the-counter drugs from Wockhardt Ltd in the United States. The acquisition by the company's fully owned subsidiary Glenmark Pharmaceuticals Inc, USA includes the approved abbreviated new drug applications (ANDAs) for famotidine tablets (10 mg and 20 mg) used to treat and prevent ulcers in the stomach and intestine, including indigestion, heartburn, and acid reflux treatment drug Lansoprazole delayed-release capsules USP, 15 mg, among other drugs.
9. What pricing options are available for accessing the report?
Pricing options include single-user, multi-user, and enterprise licenses priced at USD 4750, USD 5250, and USD 8750 respectively.
10. Is the market size provided in terms of value or volume?
The market size is provided in terms of value, measured in billion.
11. Are there any specific market keywords associated with the report?
Yes, the market keyword associated with the report is "GERD Industry," which aids in identifying and referencing the specific market segment covered.
12. How do I determine which pricing option suits my needs best?
The pricing options vary based on user requirements and access needs. Individual users may opt for single-user licenses, while businesses requiring broader access may choose multi-user or enterprise licenses for cost-effective access to the report.
13. Are there any additional resources or data provided in the GERD Industry report?
While the report offers comprehensive insights, it's advisable to review the specific contents or supplementary materials provided to ascertain if additional resources or data are available.
14. How can I stay updated on further developments or reports in the GERD Industry?
To stay informed about further developments, trends, and reports in the GERD Industry, consider subscribing to industry newsletters, following relevant companies and organizations, or regularly checking reputable industry news sources and publications.
Methodology
Step 1 - Identification of Relevant Samples Size from Population Database
Step 2 - Approaches for Defining Global Market Size (Value, Volume* & Price*)
Note*: In applicable scenarios
Step 3 - Data Sources
Primary Research
- Web Analytics
- Survey Reports
- Research Institute
- Latest Research Reports
- Opinion Leaders
Secondary Research
- Annual Reports
- White Paper
- Latest Press Release
- Industry Association
- Paid Database
- Investor Presentations
Step 4 - Data Triangulation
Involves using different sources of information in order to increase the validity of a study
These sources are likely to be stakeholders in a program - participants, other researchers, program staff, other community members, and so on.
Then we put all data in single framework & apply various statistical tools to find out the dynamic on the market.
During the analysis stage, feedback from the stakeholder groups would be compared to determine areas of agreement as well as areas of divergence